Incyte (INCY, Financial) experienced a significant stock movement, dropping 5.04% to $72.09 per share. The trading volume reached 586,711 shares with a turnover rate of 0.30% and a price fluctuation of 5.08%. Recent financial reports show Incyte's revenue at $1.138 billion, net profit at $106 million, and earnings per share at $0.55, with a high P/E ratio of 801.67. Among 28 rating institutions, 46% recommend buying, 50% suggest holding, and 4% advise selling.
Incyte specializes in small molecule drug discovery, with key products like Jakafi for rare blood cancers and graft-versus-host disease, developed with Novartis. Other drugs include Olumiant, Iclusig, Pemazyre, Tabrecta, and Monjuvi. The company also has a robust pipeline in oncology and dermatology.
